Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study
- PMID: 16213868
- DOI: 10.1016/j.fertnstert.2005.04.059
Role of the vaginally administered aromatase inhibitor anastrozole in women with rectovaginal endometriosis: a pilot study
Abstract
In the present nonrandomized pilot study we determined the role of the vaginally administered aromatase inhibitor anastrozole (0.25 mg anastrozole/d for 6 months) in the treatment of women with histologically proven rectovaginal endometriosis. In a series of 10 patients, dysmenorrhea, physical and social functioning, but not chronic pelvic pain and dyspareunia, improved during therapy.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
